Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00298350 | Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART. | PHASE2 | COMPLETED | 278 | — | — | Feb 1, 2006 | Jul 1, 2007 | Jul 29, 2008 | 54 | United States, Puerto Rico |
| Name | Type | Description |
|---|---|---|
| GS-9137 - A Novel HIV-1 Integrase Inhibitor | DRUG | - |
Inclusion Criteria: * HIV RNA greater than or equal to 1000 c/mL. * Failed/Failing protease inhibitor based antiretroviral therapy. * Stable antiretroviral therapy for greater than or equal to 30 days prior to screening. * Negative Serum Pregnancy Test. * GFR by Cockcroft Gault greater than or equa...